





<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  


<head>
      <script type="text/javascript">
    var otsuka_dl = { 
    "page": {
        "business_function": "commercial", 
        "therapeutic_area": "nephrology", 
        "business_affiliate": "oapi", 
        "site_language": "english", 
        "brand_name": "jynarque", 
        "side_of_brand": "hcp", 
        "indication": "autosomal dominant polycystic kidney disease (adpkd)", 
        "root_domain": "jynarquehcp.com"
    } 
};
  </script>

        <title>ADPKD Progression | HCP JYNARQUE® (tolvaptan) tablets</title>
    <meta charset="utf-8" />
<meta name="description" content="Find info on the progression of ADPKD &amp; risk factors associated with rapid disease progression. See FULL PRESCRIBING INFORMATION, including BOXED WARNING." />
<meta name="keywords" content="ADPKD, ADPKD disease, ESRD, complex kidney cyst growth rate, eGFR, how fast does chronic kidney disease progress, autosomal dominant polycystic kidney disease, end stage renal disease, tolvaptan, JYNARQUE" />
<link rel="canonical" href="progression.html" />
<meta name="google-site-verification" content="S979W9LEDXsQQvi7sUkEAwBRLEs0M_9EhYns57YIycs" />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="0190fcfe-c0de-7b85-b039-75fd69273f8a" defer="defer"></script>
<script type="text/javascript" defer="defer">
  function waitForElm(selector) {
    return new Promise(function (resolve) {
      if (document.querySelector(selector)) {
        return resolve(document.querySelector(selector));
      }
      const observer = new MutationObserver(function (mutations) {
        if (document.querySelector(selector)) {
          observer.disconnect();
          resolve(document.querySelector(selector));
        }
      });
      observer.observe(document.body, {
        childList: true,
        subtree: true
      });
    });
  }
  function oneTrustAddFont() {
    const link = document.createElement('link');
    link.rel = 'stylesheet';
    link.type = 'text/css';
    link.href = 'https://fonts.googleapis.com/css?family=Montserrat';
    document.getElementsByTagName('HEAD')[0].appendChild(link);
  }
  function addMeta() {
    const meta = document.createElement('meta');
    meta.name = 'viewport';
    meta.content = 'width=device-width, initial-scale=1.0';
    document.getElementsByTagName('head')[0].appendChild(meta);
  }
  function oneTrustBannerFooterFix() {
    const divSelector = document.querySelector('#onetrust-button-group-parent');
    const elementDiv = document.createElement('div');
    elementDiv.className = 'ontrust_logo';
    elementDiv.innerHTML = "<div class='green-logo'> onetrust</div><div class='text-logo'>Powered by</div>";
    divSelector.parentNode.insertBefore(elementDiv, divSelector.nextSibling);
    document.getElementsByClassName('ot-pc-footer-logo')[0].children[0].removeAttribute('href');
  }
  function oneTrustBannerOtherFix() {
    var p = document.querySelectorAll('.ot-accordion-layout p');
    Array.prototype.forEach.call(p, function(el) {
      el.innerHTML = el.innerHTML.replace(/&nbsp;/gi, '');
    });
    let tabindex = 2;
    document.querySelectorAll('#onetrust-button-group button, #onetrust-button-group input').forEach(function (element) {
      element.setAttribute('tabindex', String(tabindex));
      if (tabindex === 2) {
        tabindex = 1;
      } else if (tabindex === 1) {
        tabindex = 3;
      } else {
        tabindex++;
      }
    });
    document.querySelector('#onetrust-policy-text a').setAttribute('tabindex', 1);
  }
  function oneTrustSettingsButtonFix() {
    const acceptBtn = document.getElementById('accept-recommended-btn-handler');
    const rejectBtn = document.getElementsByClassName('ot-pc-refuse-all-handler')[0];
    const container = document.getElementsByClassName('ot-btn-container')[0];
    container.prepend(acceptBtn, rejectBtn);
  }
  function oneTrustSettingsOtherFix() {
    const modelElement = document.getElementById('onetrust-pc-sdk');
    document.addEventListener('focus', function (e) {
      const focusableElements = modelElement.querySelectorAll('a[href], area[href], input:not([disabled]), select:not([disabled]), textarea:not([disabled]), button:not([disabled]), iframe, object, embed, *[tabindex], *[contenteditable]');
      if (!Array.from(focusableElements).includes(e.target)) {
        Array.from(focusableElements)[0].focus();
      }
    }, true);
  }
  oneTrustAddFont();
  addMeta();
  document.addEventListener('DOMContentLoaded', function () {
    waitForElm('#onetrust-banner-sdk').then(function () {
      oneTrustBannerFooterFix();
      oneTrustBannerOtherFix();
    });
    waitForElm('#onetrust-pc-sdk').then(function () {
      oneTrustSettingsButtonFix();
      oneTrustSettingsOtherFix();
    });
  });
</script>
<script></script>
<link rel="preconnect" href="https://fonts.googleapis.com/" />
<link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin="anonymous" />
<link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,300;0,400;0,600;0,700;0,900;1,300;1,400;1,700&amp;display=swap" type="text/css" />
<script src="https://assets.adobedtm.com/3f0d2e2dbd42/313fd7baa8af/launch-bacdce8b01b7.min.js" type="text/javascript" async></script>
<meta name="format-detection" content="telephone=no" />
<link rel="icon" href="../sites/g/files/qhldwo11641/files/favicon.ico" type="image/vnd.microsoft.icon" />
<script type="application/ld+json">{
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "audience": "Clinician",
    "specialty": "Renal",
    "url": "https://www.jynarquehcp.com/adpkd/progression",
    "headline": [
        "Measuring kidney function alone may not reveal how ADPKD is progressing1,3",
        "Changes in kidney size often precede kidney function decline",
        "Patients presenting with a rapid decline in eGFR are already experiencing rapid disease progression5,6*",
        "ADDITIONAL FACTORS TO CONSIDER REGARDING ADPKD PROGRESSION",
        "IDENTIFY RISK FACTORS ASSOCIATED WITH THE RISK OF RAPID PROGRESSION"
    ],
    "abstract": "Assessing kidney size can help predict the rate of future kidney function decline",
    "description": "Nearly 50% of patients with ADPKD will reach end-stage kidney disease (ESKD) by age 60",
    "name": "ADPKD Progression",
    "breadcrumb": {
        "@type": "BreadcrumbList",
        "itemListElement": [
            {
                "@type": "ListItem",
                "position": 1,
                "item": {
                    "@id": "https://www.jynarquehcp.com/",
                    "name": "Homepage"
                }
            },
            {
                "@type": "ListItem",
                "position": 2,
                "item": {
                    "@id": "https://www.jynarquehcp.com/adpkd/progression",
                    "name": "ADPKD Progression"
                }
            }
        ]
    },
    "mainContentOfPage": {
        "@type": "WebPageElement",
        "potentialAction": [
            {
                "@type": "Action",
                "name": "View video",
                "description": "Hear about predicting the rate of progression",
                "url": "https://www.jynarquehcp.com/adpkd/progression#"
            },
            {
                "@type": "Action",
                "name": "Learn how",
                "description": "Measuring TKV can help predict kidney disease progression1,2",
                "url": "https://www.jynarquehcp.com/measuring-tkv-for-ckd-staging"
            },
            {
                "@type": "Action",
                "name": "See why",
                "description": "Kidney size has been shown to be a strong predictor of the rate of ADPKD progression1",
                "url": "https://www.jynarquehcp.com/measuring-tkv-for-ckd-staging"
            }
        ]
    },
    "video": [
        {
            "@type": "VideoObject",
            "name": "RODOLFO BATARSE, MD, FASN EXPLAINS HOW KIDNEY SIZE PREDICTS PROGRESSION",
            "description": "Hear about predicting the rate of progression",
            "thumbnailUrl": [
                "https://i.vimeocdn.com/video/1752759111-2f04264f6acd83b5e011c4068e1e2e693e3d229ff125e12eeef0b4e06222b7af-d_640?f=webp"
            ],
            "uploadDate": "2023-11-13T03:46:57-05:00",
            "duration": "PT76S",
            "contentUrl": "https://www.jynarquehcp.com/adpkd/progression",
            "embedUrl": "https://player.vimeo.com/video/883901919"
        }
    ],
    "about": [
        {
            "@type": "MedicalCondition",
            "name": "Autosomal Dominant Polycystic Kidney Disease",
            "alternateName": [
                "ADPKD",
                "Autosomal Dominant Polycystic Kidney Disease (ADPKD)"
            ],
            "description": [
                ""
            ],
            "riskFactor": [
                "If a patient presents with any of these independently validated risk factors, they could be appropriate for treatment.",
                "TKV greater than expected for age",
                "Overweight and obesity (BMI greater than 25 kg/m2)",
                "Family history of ESKD at or before age 58",
                "Hypertension before age 35",
                "Urologic events before age 35 (gross hematuria, cyst infection, or flank pain related to cysts)",
                "Protinuria and microalbuminuria",
                "Truncating PKD1 mutation"
            ],
            "epidemiology": [
                "The rate of progression in ADPKD is variable from patient to patient",
                "Even though ADPKD impacts all races, research shows that patient outcomes, such as early diagnosis and treatment of ADPKD, may vary by race and ethnicity attributed to social determinants of health (SDOH). Though more extensive research is needed, based on the available data, it's important to consider the following: In a nearly 10-year (2004-2013) retrospective cohort study that included 23,647 patients with ADPKD, Black patients with ADPKD reached ESKD approximately 1.5 years faster (54.4 ± 13 years of age) than White patients with ADPKD (55.9 ± 12.8 years of age)8. In one study evaluating the onset of ESKD in patients with ADPKD, Black patients who also had the sickle cell trait reached ESKD approximately 10 years earlier (n=l3; range 28-50, averaging 38.2 years of age) than Black patients without the sickle cell trait (n=9; range 36-57, averaging 48.1 years of age)9"
            ],
            "signOrSymptom": [
                "Patients with ADPKD may remain asymptomatic for years while the disease progresses, likely due to compensatory hyperfiltration1,",
                "Enlarging cysts compress surrounding nephrons and may be causing damage even when kidney function remains normal1"
            ]
        },
        {
            "@type": "MedicalTherapy",
            "guideline": [
                "Strong CYP3A Inducers: Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers",
                "V2-Receptor Agonist: Tolvaptan interferes with the V2-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a V2-agonist"
            ],
            "adverseOutcome": [
                "Most common observed adverse reactions with JYNARQUE (incidence &gt;10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia."
            ],
            "seriousAdverseOutcome": [
                "Serious Liver Injury: JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.",
                "Hypernatremia, Dehydration and Hypovolemia: JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.",
                "Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE."
            ],
            "contraindication": [
                "History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease",
                "Taking strong CYP3A inhibitors",
                "With uncorrected abnormal blood sodium concentrations",
                "Unable to sense or respond to thirst",
                "Hypovolemia",
                "Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product",
                "Uncorrected urinary outflow obstruction",
                "Anuria"
            ],
            "recognizingAuthority": {
                "@type": "Organization",
                "name": "U.S. Food and Drug Administration",
                "alternateName": "FDA",
                "url": "https://www.fda.gov/"
            }
        },
        {
            "@type": "Drug",
            "Name": "JYNARQUE®",
            "nonProprietaryName": "tolvaptan",
            "activeIngredient": "tolvaptan",
            "alternateName": "JYNARQUE (tolvaptan)",
            "dosageForm": "tablets",
            "administrationRoute": "oral",
            "doseSchedule": [
                {
                    "@type": "DoseSchedule",
                    "frequency": "Daily",
                    "doseUnit": "mg",
                    "doseValue": [
                        "60",
                        "90",
                        "120"
                    ],
                    "targetPopulation": "adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)."
                }
            ],
            "offers": {
                "@type": "Offer",
                "description": "Eligible patients pay as little as $10 per month for JYNARQUE*",
                "price": "10",
                "priceCurrency": "USD",
                "url": "https://www.jynarquerems.com/"
            },
            "pregnancyWarning": "Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy.",
            "breastfeedingWarning": "Advise women not to breastfeed during treatment with JYNARQUE.",
            "warning": [
                "JYNARQUE® (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported",
                "Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity",
                "Because of the risks of serious liver injury, JYNARQUE is available only through a Risk Evaluation and Mitigation Strategy program called the JYNARQUE REMS Program"
            ],
            "image": "https://www.jynarquehcp.com/sites/g/files/qhldwo8636/themes/site/themes/custom/jynarque_hcp/assets/build/img/jynarque-logo.png",
            "manufacturer": {
                "@type": "Organization",
                "name": "Otsuka America Pharmaceutical, Inc.",
                "logo": "https://www.jynarquehcp.com/sites/g/files/qhldwo8636/files/inline-images/otsuka_logo2.png"
            }
        }
    ]
}</script>

        <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_97htjIvQ15V1EfeTASftshiMIzLS36LIXVDogWwnlWQ.IJ5KA0xBsRRaiRPaWB6Sh9PN3WKo_EsNIYaw8SqYqYc1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Zru9LBZ0sAXcjonUFHSutTAZkU-sNKpHr1JGBQ4FyU0.bkPvoFYCA2Lixa4KISvTdT3EKjCHiKrtKcE261byVx01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_kzULKG5pzGyNLykluQb5oDJTQPcLlJKzZ5imyM6J1h8.b9DwpaiAlb0lsM657D5Lniy-cPNAkk4Cxr45yy473q41cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_uI2FntcPi0s7LE7aVRLFPdaOjEJ2AvgJxZxn7U_KEpU.uS1FFwOJYeXSeF3bIVSvkMkrHh5opqqW_F79rAx63B01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_LyrrR6JZO8eTCViUPzg899V1r3IBqMYsy9zQoA-d_xo.Awf46AhlxtFml2KQ8H4-E0dZzxzlJb1Ua0P5_ptOC4k1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_YuXFCqJ6Mh9c2Lz522vxxQKwCuYdi4B4eglcgrxGnjc.xk_yrolxl9EFVCS6-YD3__eEEiB4lkwtBVMLZeTfMbA1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Awu9YtmWu_taaaaJKswYqKQEUWlATiU0b-9Ka6etFfU.pYA92qiAPS662AtCQt6lMeZYgkI683UmfkdP-4BIymA1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_yIJuzHvo1e460jlmqttlj52OMZk0ZV7QmKCy-1vP5ZI.qAT_vNKdppWlPfwRvdNPIJfErkIfxMw2j_eesucANOI1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_xnDYBl4OD9snX7Sf9EyJ9VkzRg71lff1OegyGLU8z1w.l_5ZkiCBh5EcPa_3_oVW7iVMoKNAq5rw47oEzn5A4uM1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_gfUtLDXi72df47AexuJ-vm_wJb2QkME0vEvBnJxO6dA.x5nsh_uKblK9k6iDq9xx7vDex30jZc5ML0YXij4JCf01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_CYXnyo1qFoxHAoBBNsSqN8PVNbP8sxeQ_LtauZ50Wgs.g1uXGwNn2HpE6NbJGbnMjYWIh7kyfoVz_UhSlBh2o3s1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_QF7anExUIQ9m7lRlQYpqk7QebuejK_k7Tyzw3UgZ-hg.PZJw_IXbQZH7i6WEC-FHNDBoI3_PTyzLEmC7wWy4oTU1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_7QllbjqoprdCwoIdo3V7DWqJKkTBOzMJn-xZmsutiww.8xdGy7dXc6zJNYRxgF4k0vgBhKloby5N-_V1MMOlg8A1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_hnJTGN1fzih_ZZssV428NML2NhpFxXlJrqaLNgE8CHo.F9pmb7LygmrpoeT1fXJA7PaAVf2oWybBXF5F5Eihki41cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css__13fw7LchbE-h7zw4b3GPIwiFWcaKaefv7L39uOe9so.KNMtBlCBCom77JyoWGB48Q3ueDS7rzZa_7XYX8jrDaA1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_0jPT-BWLonFoD1a1XPcxcniBn9WgukRnniaE-xYrMIs.eYuzxX6GcmG8wPZRhL7aCvvGdgilCJbuAMMEoRSvz4o1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_wcTRp4Ty5SGu4F6Mj_Src4xCVH1pAn1ZKdFhbgibbUI.Sk-ip5PYfIjxUJ83DbxAtt7sIYi2qRj5I2X4c7e8Vm01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_XYJeCymlgeYq2fA8gUC7CjnYFGGkur-vgRftab7u22k.kpMc62oK0cmz6PxvM1ud_W8MfI7jbwibsQJBwUKnj6o1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_GbvmbJJu3etNuvRxzgpArn9FbrGIPob5sKfVZm03KVw.b0Zuw7zuYwqRxAI1V79cTc_023d639V2bQ6KyuEtbY01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Q6hS9heFRWwmGWvo9WsD_D6nDHdUaUnYt6sC6_oX9L8.KZBkzzAnxe-rSrbfNF3hMC36Vi24PspRllNxk4SA9Ww1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_41w6dBZ448pJSogyLgoToui9MDm8KnZHhhxIUFUonds.PQ-2T_xzJKQYbbkpGgIM9A4s115DO680EaZM47Z16XI1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_JCU_zSqQm3rvBIXWevl-Uch6AS6Fms27h_AxAbdSM2A.2mNgp1qsab5wdrSlpKLQv707xKZ0u6LnqctpgDVxkVk1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css__7a65Qsn2GbI6R4HiSGaSbf2n93vUm8S71hKr7aus8Y.0Qb5zpcCHmzpoF5ZOnDsfklWZn6rg3JsnrG0c7cJ-441cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_PRpLCpZQr4zTfafBQvuU6Ai1fdWr3UHToA3uiawHjkM.fLPfLB0XwmNrMgpuaRfK4T-BBNy7nDIXycFgFzdHoEQ1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_2fOIiKYvhnv1KtlkfBN2k0dROF50_VqtX1AygAXbRUU.a_ZLSp52H6ZconNljM9h1TZl4ovw7N0npH7nKInNWJg1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Z-5TKx9kThxW5rYM3vQRCBc8GEdIN_NvKS9iqhDQafw.RyxC-gT9frmBMijOhY3C3K32AabFm7-q9HkDsnP6XHU1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Q7zLgQvyD3dkOHXnT2wFwjtThfQupYWs-a29sqLPi4I.NBaa9xsCtF_rCNvid3JjjAs77Sb-JtnwFbAZvmTkOJs1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_B_2jVuT6jLLyb7aSeSEqk36PnVz0mEI5zK7uqVBaJLw.smsRBGGy-MttVliRuPwj_TEI4mBHLeiSE32C0BkTq6M1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_kJqax_RkZBAk2I3Nq_rTD9LHc0oMwWKlanYK42ORIfM.zTSiciBJCN04ULznc2T1MWG59Py-6ONyTHVVm-YCHX41cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_vOD9-5JiqhFy7oiIOzO00o2XLgmR6XH8SUL8LL585Vc.8e6pTB1_nGdHUV4devYGGEmOgZeQXykLw4UdpB-9VYg1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_syNh2ZBM2xlmOdBPf0FR8w7O-hHQEBa956Kp_ldOSBg.xkGZo2gAdcfeCasz9E7IXM7UlmN8zg2sNe-DUmghXI01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_q2E2y5MBPRf422vpPN0DME5tgpDakJKU8shGsBJGndg.qvqk-z17E7JlX9pYx8b0C1UIaYryHrpXqqt4Sdflos01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_kPUtqisf0lrHdJsPV-HJ8wEHOFRbSDxP-pzEt2drCg8.j317pwJpjGUayMMKAkpZNtp2AGp5H841Sotc8GzQsmA1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_n5uyd-zeqJWj3ELED4-FGpz1IY1LtaHa9Z89XwxVFD8.TcntdJwJgyDxqzXMEqJiT-ivM2sityt4xai9fNYIhN01cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_3-74lGc_qnWeX8UeqKX-LZDQJky2QvbaHFfo4iNTZ6k.POmC--YL2K5Oj8dGp36jOmTLjLa3WnQ1Klk-RmN5cKg1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Rz4CyfU-tt37njBy44WX-XrS4zxnMhF_6Go4o7UwLGI.79bAlAvX0LU9yDuY5LxmPLL7t8w3aVVw1vo8avMA8kA1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_2q3_cDI6RdqHnRwH_XgoPOAwo9FXO-tcqG_yT6CPe9s.l458SJWUrwPoMnJnZ_5qDN0jqPz6K5dCJoQ9UXnA_DI1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_0HuNciDfYnF1bgCrWDJ7vWP6DBbES-2NaoX7LS-7J7w.sGFI40X4eJmPcLu8FKNKbJRZE9vl-RCYCItbleoETAc1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Lln5SjQMuv2n0S-BExbI8cautmTrPcQVykeaA52uFro.s9dBNdMMOtzUsW-YvDIx7BASbgV1sw0AIYdtS9bmP9k1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_Z-BUkoxvUPU7EMoLzEuJoJtL0q7CWnxtBecdp5w__K0.pKCo9b7hBoy588SkytPsvDctX00qlbdiZkL50y8o6W41cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_vmO9LJyCcGU1n7Cjk3fgXsXlBuBpLg9YzG2oyboWnAM.7JnbAsDXCof-AqJrefP-9PXjPDv8z66ptAsDllYQr641cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_MCt3mn2BRlH9NZKS7MdM7wWfnp-dm2AkU4KVMbt3EyQ.L2SSSnCwWtoQBxhUKpTXhmLYmn6R6PZ-KU4ouXzLIVc1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_GdA3_m6b4En_7Q-k0AOowc4PYrKdO0VwYv1FlMcUG6k.DVcSnHmZHqNuqyQRoSOEPha2j2DKmTnfQ8uMuCVJluw1cee.css?t5xpr9" />
<link rel="stylesheet" media="all" href="../sites/g/files/qhldwo11641/files/css/optimized/css_GmyqFQFQe25qXoOyEGVD699zKQpLw_GqHA7ZPIgbbw4.7ZO1nmmOSbqX0BcPwxfG0l3f23_Kbss-E02-PzWTtN41cee.css?t5xpr9" />

    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/2","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/qhldwo11641\/themes\/site\/themes\/custom\/jynarque_hcp"},"pluralDelimiter":"\u0003","gtag":{"tagId":"","consentMode":false,"otherIds":[],"events":[],"additionalConfigInfo":[]},"suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJx9kGtywyAMhC_kmCNp1qBiGoEojyS-fUnSTuK26R8GrVaabwWnC5OgJ7saPBWTV_XC1OCNH8_PesY7LnsxTu9bQvnoTKvNxvbaNB4yPM9w-egOuagvXGvQtLd60QVyqG2TkPy-l9TxbCFCTQm2_RrOKPAFea2zVRHkGpbBVPiNCyfL9R97zJo4NToPAUV7ci_NUR2EBt_xpSXxpdE1L115tbeXzlNwrANx5Nl7ToHPA-x2uvuqFprwpK32I-ixwiyoD7mEE-xG10ASMAJFdgHmu20jIYfpadqVniHzE1JPuS8S6spuyitKBIUazOP7t0qu4MxlumWhLNi4mHuBnKe61cbxDnvL9pVwXLMLfwLDGPwm","theme":"jynarque_hcp","theme_token":null},"ajaxTrustedUrl":[],"gtm":{"tagId":null,"settings":{"data_layer":"dataLayer","include_classes":false,"allowlist_classes":"google\nnonGooglePixels\nnonGoogleScripts\nnonGoogleIframes","blocklist_classes":"customScripts\ncustomPixels","include_environment":false,"environment_id":"","environment_token":""},"tagIds":["GTM-W8LVZL2"]},"privacy_compliant_media_settings":{"enabled":1,"general":{"error_cmp_not_found":"Consent management is currently disabled, website functionality may be affected. Please try reloading the page."},"youtube":{"enabled":0,"cat_id":"C0002","dependent_cat_id":"C0004","modal":{"description":"To start your video we need your permission to use YouTube cookies. These cookies help us make other video recommendations specific to your interests.","consent_label":"Allow YouTube cookies","morelink_label":"Learn more about cookies","morelink_url":"javascript:OneTrust.ToggleInfoDisplay();"},"overlay_image":null},"vimeo":{"enabled":1,"cat_id":"C0008","dependent_cat_id":"C0004","modal":{"description":"By clicking \u0027Accept\u0027, you will enable functional cookies that are necessary for the video\u0027s playback on this platform. These cookies can be reviewed \u003Ca  href=\u0022javascript:OneTrust.ToggleInfoDisplay();\u0022\u003Ehere\u003C\/a\u003E and adjusted at any time by clicking the shield above. Want to know more? View our \u003Ca target=\u0022_blank\u0022 href=\u0022https:\/\/www.otsuka-us.com\/privacy-policy\u0022\u003EPrivacy Notice\u003C\/a\u003E.\r\n\u003Ca class=\u0022otsuka-pcm-consent-link\u0022 href=\u0022javascript:OneTrust.ToggleInfoDisplay();\u0022 role=\u0022button\u0022 aria-label=\u0022Privacy Notice\u0022\u003EPrivacy Notice\u003C\/a\u003E","consent_label":"Accept","morelink_label":"","morelink_url":""},"overlay_image":null},"buzzsprout_podcasts":{"enabled":0,"cat_id":"C0002","modal":{"description":"To start your podcast we need your permission to contact Buzzsprout. This allows us to place a podcast player widget on the page.","consent_label":"Allow Buzzsprout player","morelink_label":"","morelink_url":""},"overlay_image":null},"orbita_live_chat":{"enabled":0,"cat_id":"C0002","widget":{"wrapper_id":"chatbot-wrapper","html":"\u003Cdiv class=\u0022with-default-orbita-widget\u0022\u003E\r\n  \u003Cbutton class=\u0022chat-widget\u0022 aria-label=\u0022Show Chatbot\u0022\u003E\r\n    \u003Cdiv\u003E\r\n      \u003Cdiv class=\u0022chat-bubble\u0022\u003E\u003C\/div\u003E\r\n      \u003Cp\u003EChat\u003C\/p\u003E\r\n    \u003C\/div\u003E\r\n  \u003C\/button\u003E\r\n\u003C\/div\u003E","css":""},"modal":{"description":"To open the live chat we need your permission to contact Orbita. This allows us to place a live chat widget on the page.","consent_label":"Allow Orbita live chat","morelink_label":"","morelink_url":""}}},"react_videos":{"defaultSettings":{"react_player":{"classname":"react-player"},"_core":{"default_config_hash":"AgTySXb9ToBKFSHFe-ObGGqtf34C4xf1g60vpc6Dqd8"},"classname":".react-player","classname_pause":".close","playerType":"simple","thumbnail":0,"width":"100%","height":"259px","buttonText":"Play Video","autoplay":1,"muted":0,"controls":1,"responsive":0,"loop":0,"previewPlayButton":1,"audio":{"classname":".react-audio-player","classname_pause":".close","playerType":"simple","buttonText":"Play Audio","autoplay":0,"muted":0,"controls":1,"loop":0},"cookies":[{"external_services":"you.com","categories":"C0002, C0003","message":"You can\u0027t play the video.\u003Cbr \/\u003EPlease apply Functional and Analytics cookies.","button":"Allow cookies"}]},"videos_list":{"video-embed-field-provider-786-0":{"playerType":"simple","thumbnail":"1","buttonText":"Play Video","autoplay":"1","controls":"1","responsive":"1","previewPlayButton":"1","muted":0,"loop":0,"react_player":{"classname":"react-player"},"_core":{"default_config_hash":"AgTySXb9ToBKFSHFe-ObGGqtf34C4xf1g60vpc6Dqd8"},"classname":".react-player","classname_pause":".close","width":"100%","height":"259px","audio":{"classname":".react-audio-player","classname_pause":".close","playerType":"simple","buttonText":"Play Audio","autoplay":0,"muted":0,"controls":1,"loop":0},"cookies":[{"external_services":"you.com","categories":"C0002, C0003","message":"You can\u0027t play the video.\u003Cbr \/\u003EPlease apply Functional and Analytics cookies.","button":"Allow cookies"}],"url":"https:\/\/vimeo.com\/883901919","playing":true,"playerSettings":{"playerType":"simple","thumbnail":"1","buttonText":"Play Video","autoplay":"1","controls":"1","responsive":"1","previewPlayButton":"1","muted":0,"loop":0,"react_player":{"classname":"react-player"},"_core":{"default_config_hash":"AgTySXb9ToBKFSHFe-ObGGqtf34C4xf1g60vpc6Dqd8"},"classname":".react-player","classname_pause":".close","width":"100%","height":"259px","audio":{"classname":".react-audio-player","classname_pause":".close","playerType":"simple","buttonText":"Play Audio","autoplay":0,"muted":0,"controls":1,"loop":0},"cookies":[{"external_services":"you.com","categories":"C0002, C0003","message":"You can\u0027t play the video.\u003Cbr \/\u003EPlease apply Functional and Analytics cookies.","button":"Allow cookies"}]},"light":"\/sites\/g\/files\/qhldwo11641\/files\/2023-11\/video-explain-progression.png","displayThumbnail":1,"displayVideo":0,"id":"video-embed-field-provider-786-0"}}},"user":{"uid":0,"permissionsHash":"9ce7e3d0a53d6f666750a985c111fdd22308fb0fdb5f15c0fdda00c8dcaa54f4"}}</script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_dxIVcwvQ00owLGoUGPTfRYXU-T5rnj8Xi0cXfb3Kn58._JqT3SQfawRcv_BIHPThkBvs0OEvtFFmqPF_lYI_Cxod734.js?v=3.7.1"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_w0iO3No0CsyHgJmryEbhwpkh5zx6m6dhvawBt4ufwyA.HRN_m4FplP890kDvBJQuv0fEgTHDKwrMZA2zBldV1JYf700.js?v=1.0.1"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_Hpe5jrMuKXrV4HSTMApXJsNBxraAgcHUrTjxkwWKqy8.9H1W9OQqD9V27idEVOJMCFAQtGS4Scq-gAQciKr0U2Mfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_V1oRQ-kJlXBZaEklOtPUe_1t8-l0RS94HJ3gsqxKikc.LMtm7OsF5tFcpxpmBexOddu30l-Xz-FUCSBPovfiEt8fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_KRjtvzl6UujB23-j_sF6dqOcbqg2z8ej98A8RU9bGsg.kjk12BMQYgWzHTlTsh40oAfzJ1jsDD0rpt092h-M9ukfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_rJQeYB7caXNCdmgzJ4t5f6f6CrVuk9_CJlqK8yDBzqk.QLD7mKey3phzumqz3uRKIHY2nqqKo_plzIfGrgeQ5Ycfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_pbrt6BW6zk2scxcVck6pKOhrsnS-4n6mdUeoPTfK2aM.F15X2YCXNVRiXJFw9bAWTN9GXU1HaAbvYHvOoFmnbLUfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_CbOM1f2ZQjSvD29Vzs3nHYsIjSyprydKvJ38uk-EKzQ.dAXI56pV2ZPn9QGfyd-mmPdBCd_VlavLN59BjPAgNOgfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_1_Qr-HDXqlP8qV9oE0Levmwx3Sc1ldDn6Q9QvWEYY6E.XXTdDFNiWNbao5RRs1Aq-_G2fwGOGtyrrBgSr48Pr6wfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_yt_B6-UYT74y4dRKoGQ9gfLb0O0RDb4vG2LIGOYlHq8.-UGjQblMTO_e3Grk02Go8eAWHwbL6GT0oAl-h-CgK5Qfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_OYMUXIYk_UxVlsQSqo3_hSK3aC6qbx7cz9wNrtTse48.D7Do9Gn7KAOch1JHc7ma8CZHkvZvUTPAc5nIoo3LX44fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_A7R00KDzeuDMEsk6DOs_s2ZrOjO5c23zgXuffR4Khqc.q6qxxfVF7-gZME3a3JPerO2q6sv01F6mQnVPwcmknYofe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_4VhSX4lEyBg9lxgOnT6eUHtdfwq4GgGv6TSm_aWIhzc.msJZjs5u5RGmKA2fbhFxLGexUv1x2UOibCSs8rzkw1Ufe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_VycJ3FTVVaVyhSCcLXYEaSJoilQ8WxeImUFAjqgR5Y8.ouOM0Q5oYPfUBV8lTR3cCyJG56DQNwRTOVgi8IFXBrAfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_QZ6R3WHZ2xvc16JcQ7QBGg7ZW5Q69JxQSKxhelKIbIE.rnfvk6uzW1ISnGjxzePWaH83MAcUkTOsSGF6xij2QAsfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_SpWiM_QFpYbnP3qrlmV1Aa2OGQVC1G0okd3jErKS1EI.Cz8_DwPQcpJrjdTZvBKdqWS7V0abyjGDgrVg6Diy3jkfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_shtMqRNOVBaAvLi9-CpiCI1loPsDLJlEM8e0qdxIyaA._ljAZbtHeBUPsD_JTpPHK9XLnZ-Bh8IIR0gfaERLf0kfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_J05cWfCFFxc6Ntk7FqEMfp2MqvFE0LYhqPR-d5pkpX4.eRBP0BbEW9K4axpZn5GrBrvbQysogv9ziF_qly6y9P0fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_XrfmCmDqLTCEPh8gnU8hVIYf5mJPXNeZp91Zu1g8f9Y.i3qujr4t4NUUzwk0bY4rUPAZgLDWLpH4I0Ht5U7c2Gsfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_DB1pt9EyFJ14MM4u0q_UUdhcwWPwrgl0M8Ao_U1cQKw.1HGXCu8xDCZ9D4t4OUEJBVbpMoVuuCDmld0Orcde48Ufe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_xTMVqsdfgSLZsrDVnB0yeJ_u8fjPX7MQHI1nVihqNuE.7B-a0BsG-0oGVyrcfb37AxOKeNquBdl8lk3CyiHXfeUfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_gEmjNg-vrsVI816UzVFe6X3vlSx0FTpPgKUR0axgrXs.aT1b17yuuFOZ02MCX5ONYrorBiyoVdHn6EFMtlXyDCAfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_trjIfy6wGxnxz9PVSI8rA84dA6HxX_Lw5W4uUlw0Xs0.-KbTIsNarrWDUf2UHG7fElVJxl72-Pmuf_1NbApB5A0fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_2hr-YHySYMDuptPCwhH1H7CfNShEa93koPpOo_581D4.fU-RbWLSh2I8Ytqntu1-ArKZ9OVXly0tO-X8U0Ety6Ife04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_WmhavmnC0K35xZ9vLX51qtRqFT74puvZXIMWnNUYpbM.HmKlReEYCiV9GnfhxV81WuXqMJ6i6CJEQgYJrzlXRtw0559.js?v=6.2.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_pCqeI411sVqMjF7f2fKhUUOV4yKaxxQp7FHSELuxGGc.2g5bmie0CWfVbbOg32zvwXHEUfmS0mqFc0I_Z7vrtvMfe04.js?v=10.5.0"></script>
<script src="../modules/contrib/adobe_launch/js/adobe_launch_dtm_init1cee.js?t5xpr9"></script>
<script src="../modules/contrib/google_tag/js/gtag1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_1woVuTYaOTc9db19BvtYERQ-r3zrWbaX8Iy9t_Z2qoM.pMTBYmavvxWwegzqwJmMmmYVLsQ3cxiWBi9yq_dxzNMe0a5.js?v=4.3.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_mjv4qhOv2_1-EQeYpZwvWqHcMokP3Cu36uHh9tRNXFY.CJF84Dv0PjH3KPaqgwzS-NJS45qPbXaVePB7UAw-uH8fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_ezwJb8QjKN82W11Y2widYXtFt5DfOo-fgZxIg_9sAik.s0ftg9DcYKonxRNsyujPK8mZFoHu6DwZvsB0967odSIfe04.js?v=10.5.0"></script>
<script src="../modules/contrib/google_tag/js/gtm1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/isi-state1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_J_G6YrAi5duRDJekzJ6rjnG28oqOVCu_MPQwxhSYGow.Qp9BFfZG_BWtt9YimvmtE9BSWD3fWWQmE_KLI5Eoiao1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_dgim6OgqTA_DG5wPkPdSGk_ffzUkd8ip9LwuHxVo1sI.mZ98qx_1nQtXzgDDy9reKJSzFDoo-w4yhyIdEfKAHlM1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_q7FJqCr4JCiQip_Tz2e_h4tgMP443SG2ovYc1mDfmhQ.pnyD-CkIhe1h_Jx0jtDrfSNlPJAqzILWsJ3NvZYdOtI1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_aEkVIYuSMtGvUpkRLpsx4Havd-U7CgaBzI4c8T043hY.bNn0IFRdhaUJdh1PX_eJXXz5xx_slAb_npV-mqLhAyw1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/isi-resize1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/base/bootstrap/bootstrapcd33.js?v=4.5.2" defer></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_P-oMcsV1isPQN7J_9srX5flt9fqyRhUBLJFfnVUO7_8.Uf0TeQfB8iU5YkLJufFdWdXZs7P4QlCa9W649PI35-k1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_OS7umhC2npk_k6HFrTBUOGw7IMkQkSTpjJrtCzMIIFU.mjh9oGk3WVOVcHsF6kJLjqansWN1KLh7O_3yd4FDBmg1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_bxDZKA71LpajHuuDs_IsmHcULV4iGZ5wDebNISM68Ec.QOaAi5jgG26lpVuvuNRQ1BkxXXJdSqieBPgIZrXkS9M1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/jynarque/jynarque_custom1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/mainmenu1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/anchor-scroll1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/video-react1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_nKlW0s1eP3bGjyfbSHP4guHgnuCQ2V_IbkgMZ4UdzO4.MTHCcdAQ1524jW6nLa3EtNqF_1TujsKyr8qksEY7n6wfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_KKcnkUdYKB53TMNVsf6RrHXCgsIpqtdkf2utxTGblLc.ynu_A6j2Wzd1B6Vw6BTQ8qyocstdbrEa04BlYLcbHiEfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_3V5UYvHeGVCTCI6-0G9MShZMkOTjpmWzauUa17REJYg.Skr0Jc5GUKefc-pdZvCEo932Y2orIBO4a5uHTzer7YMfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_7SLROedAOygMVqhG50yRRbiZ1w7AmAy9Wx63Se_hrEo.RHHoh3qOJXKfC_izkCzBQeHAM9lKs2tMLnwwXJQddecfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_3PPDECkkWmZprRXP5fGfqH5tOkTJcwB21__r7fjPUh4.FM0QEgk5sXswUR2j_HZSngwH1zEUr0v2J8mHf-3nglsfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_GrQl3TMVBdSFgif7bkvIVoCWbf9SY3sm8jianc5MBYI.a7xJmtDE8RvIy3x-q9FvAIJ1W6CbYZd3rd0FQNL3Q-sfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_4bZGp8eSSkr0AcYEB06FWt2zMZLqDhKxz6gEhKnO5X0.-_wJjs2BWnIoDstNCjVUMdohPAm1Cb6KMFLzNQnyetsfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_dOdL6MKe8Xi7Kps6emaAgxWRpDXYc7U7glpIUKIBOiA.XAp-Kcb5FZvnj1DJvOdVsSEE04SX1ckhOvPcQwTj6hofe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_YSBqDrGfkyMrsn-wT-lty4BnE7uEji7vl0zKC_-Z0BE.oLTnTHb9AUCZyGIMu_xYoE6Miz_LA_c24mSOzHiEwxUfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js__TF0_87cNnB7zfFuH5jalW1RMKzKj__FtRNXnDln7eA.LbmYeeNvT-Bo1K2wExK2EJO_Hm8zkO7p3Daf1NdLzbMfe04.js?v=10.5.0"></script>

  </head>
  
  <body class="isi-enabled isi-drawer-enabled custom-page--adpkd-progression section--0-adpkd section--1-progression path-node page-node-type-brand-basic-page page-node-2">
    <div class="content-wrapper">
        <div role="navigation" aria-label="Skip to main content">
      <a href="#main-content" class="visually-hidden focusable skip-link">
        Skip to main content
      </a>
    </div>
    
<header role="banner" id="header-wrap" class="menu-section">
    <div class="header-container">
      <div class="header-left">
        <div class="header-branding">
          <a href="../index.html" data-test="navbar-logo" 
            data-analytics-link='{"name":"company logo","position":"header","group":"Logo","href":"https://www.jynarquehcp.com/"}' 
          ><img src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/img/jynarque-logo.png" alt="JYNARQUE® (tolvaptan), Logo"></a>
        </div>
        <a href="#" class="off-canvas-button" 
          data-analytics-link='{"name":"Navbar Toggle","position":"header","group":"Logo","href":"https://www.jynarquehcp.com/"}' 
          data-test='mobile-menu-toggle'
        ></a>
      </div>
      <div class="header-right">
        <div class="header-intended-audience">
            <div class="region region-header-intended-audience">
    <nav role="navigation" aria-labelledby="block-utilitynav-menu" id="block-utilitynav" class="custom-block--utilitynav">
            
  <div class="visually-hidden" id="block-utilitynav-menu">Utility Nav</div>
  

        
              <ul block="block-utilitynav" region="header_intended_audience" data-test="top-menu">
              <li>
                <a href="https://www.otsuka-us.com/media/static/JYNARQUE-PI.pdf" target="_blank" class="ssp-bold mobile-separator prominent reverse-yellow mobile-shift external-link-popup-disabled">U.S. FULL PRESCRIBING INFORMATION,<br /> INCLUDING BOXED WARNING</a>
              </li>
          <li>
                <a href="#isi-top" target="_self" class="isi-jump-link ssp-bold prominent important-safety-information-link">Important Safety Information</a>
              </li>
          <li>
                <a href="https://www.jynarque.com/" target="_self" class="ssp-bold mobile-hide ext-link prominent patient-site-link ssp-bold mobile-hide ext-link prominent patient-site-link">Patient Site</a>
              </li>
          <li>
                <span>This site is intended for U.S. Healthcare Professionals only</span>
              </li>
        </ul>
  


  </nav>

  </div>

        </div>
        <div class="header-main-menu">
            <div class="region region-header-main-menu">
    <nav role="navigation" aria-labelledby="block-jynarque-hcp-main-menu-menu" id="block-jynarque-hcp-main-menu" class="custom-block--jynarque-hcp-main-menu">
            
  <div class="visually-hidden" id="block-jynarque-hcp-main-menu-menu">Main navigation</div>
  

        

              <ul block="block-jynarque-hcp-main-menu" region="header_main_menu" class="menu nav" data-test='main-menu'>
                          <li class="menu-item">
                                                            <a href="../index.html" class="home-link" data-analytics-link="{&quot;name&quot;:&quot;Home&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/&quot;}" data-drupal-link-system-path="&lt;front&gt;">Home</a>
        
        
        
        
              </li>
                      <li class="menu-item menu-item--expanded menu-item--active-trail">
                                                            <span target="_self" class="understanding-link data-analytics-click-link" role="button" data-analytics-link="{&quot;name&quot;:&quot;Understanding ADPKD&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}">Understanding ADPKD</span>
        
        
                  <div class="menu-toggle"></div>
        
        
                                <ul class="menu sub-nav">
                          <li class="menu-item">
                                                            <a href="about.html" data-analytics-link="{&quot;name&quot;:&quot;About ADPKD&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/adpkd/about&quot;}" data-drupal-link-system-path="node/25846">About ADPKD</a>
        
        
        
        
              </li>
                      <li class="menu-item menu-item--active-trail">
                                                            <a href="progression.html" target="_self" data-analytics-link="{&quot;name&quot;:&quot;Disease progression&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}" data-drupal-link-system-path="node/2" class="is-active" aria-current="page">Disease progression</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../measuring-tkv-for-ckd-staging.html" data-analytics-link="{&quot;name&quot;:&quot;Measuring kidney size&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/measuring-tkv-for-ckd-staging&quot;}" data-drupal-link-system-path="node/9">Measuring kidney size</a>
        
        
        
        
              </li>
        </ul>
  
              </li>
                      <li class="menu-item">
                                                            <a href="../mechanism-of-action.html" class="mechanism-of-action-link nav-desktop-only" data-analytics-link="{&quot;name&quot;:&quot;Mechanism of Action&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/mechanism-of-action&quot;}" data-drupal-link-system-path="node/4">Mechanism of Action</a>
        
        
        
        
              </li>
                      <li class="menu-item menu-item--collapsed">
                                                            <span class="efficacy-link data-analytics-click-link" role="button" data-analytics-link="{&quot;name&quot;:&quot;Efficacy&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}">Efficacy</span>
        
        
                  <div class="menu-toggle"></div>
        
        
                                <ul class="menu sub-nav">
                          <li class="menu-item">
                                                            <a href="../clinical-trial-efficacy.html" data-analytics-link="{&quot;name&quot;:&quot;Pivotal trials&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/clinical-trial-efficacy&quot;}" data-drupal-link-system-path="node/25991">Pivotal trials</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../non-pivotal-data.html" data-analytics-link="{&quot;name&quot;:&quot;Non-pivotal data&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/non-pivotal-data&quot;}" data-drupal-link-system-path="node/26061">Non-pivotal data</a>
        
        
        
        
              </li>
        </ul>
  
              </li>
                      <li class="menu-item menu-item--collapsed">
                                                            <span target="_self" class="safety-link data-analytics-click-link" role="button" data-analytics-link="{&quot;name&quot;:&quot;Safety Profile&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}">Safety Profile</span>
        
        
                  <div class="menu-toggle"></div>
        
        
                                <ul class="menu sub-nav">
                          <li class="menu-item">
                                                            <a href="../clinical-information/safety-profile.html" data-analytics-link="{&quot;name&quot;:&quot;Safety profile&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/clinical-information/safety-profile&quot;}" data-drupal-link-system-path="node/5">Safety profile</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../clinical-information/open-label-extension-study.html" data-analytics-link="{&quot;name&quot;:&quot;Open-label extension study&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/clinical-information/open-label-extension-study&quot;}" data-drupal-link-system-path="node/26066">Open-label extension study</a>
        
        
        
        
              </li>
        </ul>
  
              </li>
                      <li class="menu-item">
                                                            <a href="../rems-program.html" class="rems-link" data-analytics-link="{&quot;name&quot;:&quot;REMS&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/rems-program&quot;}" data-drupal-link-system-path="node/7">REMS</a>
        
        
        
        
              </li>
                      <li class="menu-item menu-item--collapsed">
                                                            <span class="identifying-counseling-patients-link data-analytics-click-link" role="button" data-analytics-link="{&quot;name&quot;:&quot;Identifying and Counseling Patients&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}">Identifying and Counseling Patients</span>
        
        
                  <div class="menu-toggle"></div>
        
        
                                <ul class="menu sub-nav">
                          <li class="menu-item">
                                                            <a href="../identify-patients.html" data-analytics-link="{&quot;name&quot;:&quot;Patient identification&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/identify-patients&quot;}" data-drupal-link-system-path="node/38836">Patient identification</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../patient-profiles.html" data-analytics-link="{&quot;name&quot;:&quot;Patient profiles&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/patient-profiles&quot;}" data-drupal-link-system-path="node/26016">Patient profiles</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../patient-counseling.html" class="patient-counseling-link Patient Counseling" data-analytics-link="{&quot;name&quot;:&quot;Patient counseling&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/patient-counseling&quot;}" data-drupal-link-system-path="node/38851">Patient counseling</a>
        
        
        
        
              </li>
        </ul>
  
              </li>
                      <li class="menu-item">
                                                            <a href="../dosing-information.html" class="dosing-link nav-desktop-only" data-analytics-link="{&quot;name&quot;:&quot;Dosing&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/dosing-information&quot;}" data-drupal-link-system-path="node/6">Dosing</a>
        
        
        
        
              </li>
                      <li class="menu-item menu-item--collapsed">
                                                            <span class="resources-link data-analytics-click-link" role="button" data-analytics-link="{&quot;name&quot;:&quot;Resources&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;n/a&quot;}">Resources</span>
        
        
                  <div class="menu-toggle"></div>
        
        
                                <ul class="menu sub-nav">
                          <li class="menu-item">
                                                            <a href="../expert-videos.html" data-analytics-link="{&quot;name&quot;:&quot;Video library&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/expert-videos&quot;}" data-drupal-link-system-path="node/38816">Video library</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../treatment-resources.html" data-analytics-link="{&quot;name&quot;:&quot;Treatment resources&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/treatment-resources&quot;}" data-drupal-link-system-path="node/38831">Treatment resources</a>
        
        
        
        
              </li>
                      <li class="menu-item">
                                                            <a href="../clinical-resources.html" data-analytics-link="{&quot;name&quot;:&quot;Clinical resources&quot;,&quot;position&quot;:&quot;header&quot;,&quot;group&quot;:&quot;main-menu&quot;,&quot;href&quot;:&quot;https://www.jynarquehcp.com/clinical-resources&quot;}" data-drupal-link-system-path="node/38826">Clinical resources</a>
        
        
        
        
              </li>
        </ul>
  
              </li>
        </ul>
  


  </nav>

  </div>

        </div>
      </div>
    </div>
</header>

    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W8LVZL2"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    <div  class="layout-container" >

  
    <div class="region region-messages">
    <div data-drupal-messages-fallback class="hidden"></div>

  </div>


  <main role="main">
    <a id="main-content" tabindex="-1"></a>
          <div class="layout-pre-content">
          <div class="region region-pre-content">
    <div class="views-element-container custom-block--views-block__custom-page-title-custom-page-title" id="block-views-block-custom-page-title-custom-page-title">
  
    
      <div><div class="js-view-dom-id-9b3b58d6e54ecd5813535d7600fb0d02e487a475c10e882f2d062bbce08bae77">
  
  
  

  
  
  

      <div class="views-row"><div class="views-field views-field-field-headline"><h1 class="field-content page-title"><span class="desktop-break">Assessing kidney size can help predict the rate of future kidney function decline<sup>1,2</sup></span>
</h1></div></div>

    

  
  

  
  
</div>
</div>

  </div>

  </div>

      </div>
    
    <div class="layout-content content-wrap-outer">
          <div class="region region-content">
    <div id="block-jynarque-hcp-content" class="custom-block--jynarque-hcp-content">
  
    
      

<article class="custom--adpkd-progression region-with-right-sidebar">

  <section class="node-wrapper">
    
    
    <div class="container">
      <div class="row">
                  <div class="col-md-10 col-lg-7">
            <div class="node-content">
              


                    
  <div class="clearfix measuring-kidney paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-16" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><h3 class="center">Measuring kidney function alone <span class="mobile-break">may not reveal how <span class="desktop-break">ADPKD is progressing<sup>1,3</sup></span></span></h3>
</div>
            
      </div>

                              


        <div class="clearfix paragraph content-box full-width inline-image paragraph-2286" data-test='paragraph'>
                      <div class="desktop-only tablet-only">
        


                    <div class="field_pharma_graphic ">  <img loading="eager" src="../sites/g/files/qhldwo11641/files/2024-03/measuring-kidney-function-tkv-adpkd-progression-min.png" width="540" height="263" alt="Kidney Function and TKV Over Time" />

</div>
            
        </div>
        <div class="mobile-only">
        


                    <div class="field_pharma_graphic_mobile_alt ">  <img loading="eager" src="../sites/g/files/qhldwo11641/files/measuring-kidney-function-tkv-adpkd-progression-mobile.png" width="281" height="136" alt="Kidney Function and TKV Over Time" />

</div>
            
        </div>
                  </div>
    
                              
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-54" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><div class="definitions-footnotes">
<p>Adapted from Grantham JJ, et al. <em>Nat Rev Nephrol</em>. 2011;7(10):556-566.</p>
</div>

<h3 class="center">Changes in kidney size often precede kidney function decline</h3>

<ul>
	<li>Patients with ADPKD may remain asymptomatic for years while the disease progresses, likely due to compensatory hyperfiltration<sup>1,4</sup></li>
	<li>Enlarging cysts compress surrounding nephrons and may be causing damage even when kidney function remains normal<sup>1</sup></li>
	<li>The rate of progression in ADPKD is variable from patient to patient<sup>1</sup></li>
</ul>
</div>
            
      </div>

                              
  <div class="clearfix yellow-banner paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-2281" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><p>Patients presenting with a rapid decline in eGFR are already experiencing rapid disease progression<sup>5,6*</sup></p>
</div>
            
      </div>

                              
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-1231" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><div class="definitions-footnotes"><p class="external-definition"><span class="external">*</span>Historical annual eGFR decline of ≥3 mL/min/1.73 m<sup>2</sup> (determined by multiple measurements of eGFR over 3-5 years).<sup>6</sup></p></div></div>
            
      </div>

                              

    
      
      
                  <div class="clearfix paragraph-52 paragraph reverse headline headline-cta imgtext-type" data-test='paragraph'>
        <div class="headline-inner-wrap">
          <div class="icon">


                    <div class="field_pharma_graphic ">  <img loading="lazy" src="../sites/g/files/qhldwo11641/files/cta-reach-ESKD-by-age-60.png" width="175" height="155" alt="" />

</div>
            </div>
          <div class="col1-copy">


                    <div class="field_body_copy1 "><p><span class="yellow-subhead">Nearly 50% of patients with ADPKD will reach end-stage kidney disease (ESKD) by age 60<sup>7</sup></span></p></div>
            </div>
          <div class="col2-link"></div>
        </div>
      </div>
      
      
    

                                      <div class="clearfix paragraph section-break">
    </div>
    
                              
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-2341" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><h2 id="disease-progression-slash-additional-factors-scroll-anchor">ADDITIONAL FACTORS TO CONSIDER REGARDING ADPKD PROGRESSION</h2><div class="additional-factors-wrapper"><p>Even though ADPKD impacts all races, research shows that patient outcomes, such as early diagnosis and treatment of ADPKD, may vary by race and ethnicity attributed to social determinants of health (SDOH). Though more extensive research is needed, based on the available data, it's important to consider the following:</p><ul><li>In a nearly 10-year (2004-2013) retrospective cohort study that included 23,647 patients with ADPKD, Black patients with ADPKD reached ESKD approximately 1.5 years faster (54.4 ± 13 years of age) than White patients with ADPKD (55.9 ± 12.8 years of age)<sup>8</sup></li><li>In one study evaluating the onset of ESKD in patients with ADPKD, Black patients who also had the sickle cell trait reached ESKD approximately 10 years earlier (n=13; range 28-50, averaging 38.2 years of age) than Black patients without the sickle cell trait (n=9; range 36-57, averaging 48.1 years of age)<sup>9</sup></li></ul></div></div>
            
      </div>

                                      <div class="clearfix paragraph section-break">
    </div>
    
                              
  <div class="clearfix right-padding-short paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-60" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><h2>IDENTIFY RISK FACTORS ASSOCIATED WITH THE RISK OF RAPID PROGRESSION</h2>
</div>
            
      </div>

                              
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-2336" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><h3>If a patient presents with any of these independently validated risk factors, they could be appropriate for treatment.<sup>10</sup></h3>
</div>
            
      </div>

                              


        <div class="clearfix paragraph content-box full-width inline-image paragraph-61" data-test='paragraph'>
                      <div class="desktop-only tablet-only">
        


                    <div class="field_pharma_graphic ">  <img loading="eager" src="../sites/g/files/qhldwo11641/files/2022-05/adpkd-risk-factors.png" width="424" height="498" alt="Identifying Factors of Patients at Risk for Rapid Disease Progression" />

</div>
            
        </div>
        <div class="mobile-only">
        


                    <div class="field_pharma_graphic_mobile_alt ">  <img loading="eager" src="../sites/g/files/qhldwo11641/files/adpkd-risk-factors-mobile.png" width="302" height="429" alt="Identifying Factors of Patients at Risk for Rapid Disease Progression" />

</div>
            
        </div>
                  </div>
    
                              
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-63" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><div class="definitions-footnotes">
<p>ADPKD=autosomal dominant polycystic kidney disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; TKV=total kidney volume.</p>
</div>
</div>
            
      </div>

                              



    
      <div class="clearfix paragraph reverse headline cta-next-page-nav" data-test='card'>
        <div class="headline-inner-wrap">
          <div class="linear-link-content">
            <div class="cta-body">
              


                    <div class="field_next_page_description "><p>Kidney size has been shown to be a strong predictor of the rate of ADPKD progression<sup>15</sup></p>
</div>
            
            </div>
            <div class="cta-link">
              <a 
                class="button " id="cta-62" href="../measuring-tkv-for-ckd-staging.html"
                data-analytics-link='{"name":"SEE WHY","position":"body","group":"Next page action","href":"https://www.jynarquehcp.com/measuring-tkv-for-ckd-staging"}'
              >
                SEE WHY
              </a>
            </div>
          </div>
        </div>
      </div>

    

            
              


                    <div class="field_component_references ">    <div class="clearfix paragraph paragraph--type--collapsible-references paragraph--view-mode--default" data-test="reference">
          <p>
        <a 
          aria-controls="collapse-references" aria-expanded="false" data-toggle="collapse" href="#collapse-references"
          data-analytics-link='{"name":"REFERENCES","position":"body","group":"References","href":"n/a"}'
        >
          REFERENCES
        </a>
      </p>
      <div class="collapse" id="collapse-references">
        <ol><li>Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. <em>Clin J Am Soc Nephrol.</em> 2006;1(1):148-157.</li><li>Grantham JJ, Torres VE. The importance of total kidney volume in evaluating progression of polycystic kidney disease. <em>Nat Rev Nephrol.</em> 2016;12(11):667-677.</li><li>Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. <em>Nat Rev Nephrol.</em> 2011;7(10):556-566.</li><li>Ness B, Stovall K. Current recommendations for treating autosomal dominant polycystic kidney disease. <em>JAAPA.</em> 2016;29(12):24-28.</li><li>Müller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. <em>Nephrol Dial Transplant.</em> 2022;37(5):825-839.</li><li>Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). <em>Kidney Int.</em> 2025;107 (suppl 2S):S1-S239.</li><li>Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. <em>Am J Kidney Dis.</em> 2016;67(5):792-810.</li><li>Murphy EL, Dai F Blount KL, Droher ML, et al. Revisiting racial differences in ESRD due to ADPKD in the United States. <em>BMC Nephrol.</em> 2019;20(1):55.</li><li>Yium J, Gabow P, Johnson A, et al. Autosomal dominant polycystic kidney disease in Blacks: clinical course and effects of sickle-cell hemoglobin. <em>J Am Soc Nephrol.</em> 1994;4:1670-1674.</li><li>Rastogi A, Ameen KM, Al-Baghdadi M, et al. Autosomal dominant polycystic kidney disease: updated perspectives. <em>Ther Clin Risk Manag.</em> 2019;15:1041-1052.</li><li>Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. <em>Clin J Am Soc Nephrol.</em> 2012;7(3):479-486.</li><li>Yu ASL, Shen C, Landsittel DP, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. <em>Kidney Int.</em> 2018;93(3):691-699.</li><li>Nowak K, You Z, Gitomer B, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. <em>J Am Soc Nephrol.</em> 2018;29(2):571-578.</li><li>Cornec-Le Gall E, Audrézet MP, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. <em>J Am Soc Nephrol.</em> 2016;27(3):942-951.</li><li>Bhutani H, Smith V, Rahbari-Oskoui F, et al; for the CRISP Investigators. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. <em>Kidney Int.</em> 2015;88(1):146-151.</li></ol>
      </div>
      </div>
</div>
            
            </div>
          </div>
          <div class="col-md-10 col-lg-3">
            


                    <div class="field_sidebar_cta ">



  
  
  
      
  
  
  <div class="cta-box cta-box_right-side cta-type-type1" data-test='card' data-analytics-group="Call to action">
    <div class="cta-icon">
      


                    <div class="field_cta_icon ">  <img loading="lazy" src="../sites/g/files/qhldwo11641/files/ctas/cta-measuring-total-kidney-volume.png" width="61" height="44" alt="" />

</div>
            
      
    </div>
    <div class="cta-body">
      


                    <div class="field_cta_body "><p>Measuring TKV can help predict <span class="desktop-break">kidney disease progression<sup>1,2</sup></span></p></div>
            
    </div>
          <div class="cta-link">
        <a class="button " id="cta-52" href="../measuring-tkv-for-ckd-staging.html" target="">
          LEARN HOW
        </a>
      </div>
              <div class="cta-link">
        
      </div>
      </div>
  
</div>
                              <div class="field_sidebar_cta ">



  
  
  
      
  
  
  <div class="custom--video-popup cta-box cta-box_right-side cta-type-type1" data-test='card' data-analytics-group="Call to action">
    <div class="cta-icon">
      
      


                    <div class="field_cta_media_icon "><div>
  
  


                    <div class="field_media_image ">  <img loading="lazy" src="../sites/g/files/qhldwo11641/files/2022-05/watch-video-icon.png" width="73" height="38" alt="" />

</div>
            
</div>
</div>
            
    </div>
    <div class="cta-body">
      


                    <div class="field_cta_body "><p>Hear about<br>
predicting the rate of progression</p></div>
            
    </div>
              <div class="cta-link">
        


                    <div class="field_paragraph ">


    <a
    href="#" class="modal-link button " data-toggle="modal" data-target="#view-video"
    data-analytics-link='{"name":"VIEW VIDEO","position":"body","group":"References","href":"n/a"}'
  >
        <span>VIEW VIDEO</span>
      
  </a>

<div id="view-video" class="modal fade modal-custom  video-size" tabindex="-1" role="dialog" aria-hidden="true" data-test="modal">
  <div class="modal-dialog modal-dialog-centered modal-lg" role="document">
    <div class="modal-content">
      <button type="button" class="close" data-dismiss="modal" aria-label="Close" data-test="modal-close">
        <span aria-hidden="true">&times;</span>
      </button>
      <div class="modal-body" data-test="modal-body">
        


                    <div class="field_modal_content ">
  <div class="clearfix paragraph paragraph--type--pharma-copy-region paragraph--view-mode--default" id="paragraph-7911" data-test='paragraph'>
          


                    <div class="field_pharma_body_copy "><h2>Rodolfo Batarse, MD, Fasn explains how kidney size predicts progression</h2></div>
            
      </div>
</div>
                              <div class="field_modal_content ">
  <div class="clearfix paragraph paragraph--type--video-react paragraph--view-mode--default" id="paragraph-7916" data-test='paragraph'>
          


                    <div class="field_react_video "><div>
  
  


                    <div class="field_video_embed "><div id="video-embed-field-provider-786-0" class="video-embed-field-provider-786-0"></div>
</div>
            
</div>
</div>
            
      </div>
</div>
            
      </div>
    </div>
  </div>
</div>
</div>
            
      </div>
      </div>
  
</div>
            
          </div>
              </div>
    </div>
  </section>

</article>

  </div>

  </div>

    </div>          <div class="layout-post-content">
          <div class="region region-post-content">
    


	<a id="isi-top" name="isi-top"></a>
	<section id="inline-isi-wrapper" class="section isi-section" data-test="isi">
		
		<div class="isi isi-block">
			<div class="isi-inline-title-wrap"><span class="isi-block-title"><h2>INDICATION and IMPORTANT SAFETY INFORMATION</h2>
</span></div>
			
      <div class="isi-inline-inner-wrap"><p class="subtitle subtitle-blue"><span class="nobr">JYNARQUE</span> is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).</p><div class="fake-box"><p class="box-title mobile-only subtitle-blue"><strong>WARNING: RISK OF SERIOUS LIVER INJURY</strong></p><p class="center box-title desktop-only tablet-only subtitle-blue"><strong>WARNING: RISK OF SERIOUS LIVER INJURY</strong></p><ul><li><span class="nobr"><strong>JYNARQUE<sup>®</sup> (tolvaptan)</strong></span><strong> can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported</strong></li><li><strong>Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3&nbsp;months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of&nbsp;hepatic injury can mitigate, but not eliminate, the risk of&nbsp;serious hepatotoxicity</strong></li><li><strong>Because of the risks of serious liver injury, </strong><span class="nobr"><strong>JYNARQUE</strong></span><strong> is available only through a Risk Evaluation and Mitigation Strategy program called the Tolvaptan for ADPKD Shared System REMS</strong></li></ul></div><p class="subtitle"><strong>CONTRAINDICATIONS:</strong></p><ul><li>History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease</li><li>Taking strong CYP3A inhibitors</li><li>With uncorrected abnormal blood sodium concentrations</li><li>Unable to sense or respond to thirst</li><li>Hypovolemia</li><li>Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product</li><li>Uncorrected urinary outflow obstruction</li><li>Anuria</li></ul><p><strong>Serious Liver Injury:</strong> JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD&nbsp;experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.</p><p><strong>Hypernatremia, Dehydration and Hypovolemia:</strong> JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.</p><p><strong>Inhibitors of CYP3A:</strong> Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.</p><p><strong>Adverse Reactions:</strong> Most common observed adverse reactions with JYNARQUE (incidence &gt;10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.</p><p><strong>Other Drug Interactions:</strong></p><ul><li><strong>Strong CYP3A Inducers:</strong> Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers</li><li><span class="nobr"><strong>V<sub>2</sub>-Receptor Agonist:</strong></span> Tolvaptan interferes with the <span class="nobr">V<sub>2</sub>-agonist</span> activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a <span class="nobr">V<sub>2</sub>-agonist</span></li></ul><p><strong>Pregnancy and Lactation:</strong> Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.</p><p class="reporting">To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at <span class="nobr">1-800-438-9927</span> or FDA at <span class="nobr">1-800-FDA-1088</span> (<a class="cyan ext-link" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">www.fda.gov/medwatch</a>).</p><p class="pb-2">Please see <a class="cyan external-link-popup-disabled" href="https://www.otsuka-us.com/media/static/JYNARQUE-PI.pdf" target="_blank">FULL PRESCRIBING INFORMATION</a>, including <strong>BOXED WARNING</strong>.</p>
</div>
		</div>

	</section>

  </div>

      </div>
      </main>

</div>
    
<div id="interstitial-wrapper" class="interstitial-hidden">
  <div id="overlay-mask"></div>
  <div id="interstitial">
    <div class="interstitial-content-wrap-outer">
    <div class="interstitial-content-wrap-inner">
      <div class="interstitial primary-interstitial">
          <div class="region region-interstitial">
    <div id="block-interstitial" class="custom-block--interstitial block-content-interstitial block-content-basic-block">
  
    
      


                    <div class="body "><p class="interstitial-opener">You are now leaving</p>

<p class="interstitial-domain">JYNARQUEHCP.COM</p>

<p class="interstitial-instruction"><strong>Click "I Agree" to proceed.</strong></p>
</div>
            
  </div>

  </div>

        <a href="#" id="accept-exit" class="button external-link-popup-disabled">I Agree</a>
      </div>
            <div class="interstitial otsuka-interstitial">
          <div class="region region-interstitialotsuka">
    <div id="block-otsukapropertyinterstitial" class="custom-block--otsukapropertyinterstitial block-content-otsuka-property-interstitial block-content-basic-block">
  
    
      


                    <div class="body "><p class="interstitial-opener">You are now leaving</p>

<p class="interstitial-domain">JYNARQUEHCP.COM</p>

<p class="interstitial-copy">The website you are linking to is neither owned nor controlled by Otsuka America Pharmaceutical, Inc. (Otsuka).</p>

<p class="interstitial-copy">Otsuka is not responsible for the content or services on the site.</p>

<p class="interstitial-copy">The reprint you are linking to may include information that is not contained in the product labeling. Please see the <a href="https://www.otsuka-us.com/media/static/JYNARQUE-PI.pdf" target="_blank">FULL PRESCRIBING INFORMATION</a>, including <strong>BOXED WARNING</strong>, for complete product information.</p>

<p class="interstitial-copy">Click "Ok" to proceed or "Cancel" to return.</p>
</div>
            
  </div>

  </div>

        <a href="#" id="acceptotsuka" class="button external-link-popup-disabled">OK</a>
        <a href="#" id="cancelotsuka" class="button-transparent cancel-button">CANCEL</a>
      </div>
                  <div class="interstitial iassist-interstitial">
            <div class="region region-interstitialassist">
    <div id="block-iassistpartyinterstitialoverlay" class="custom-block--iassistpartyinterstitialoverlay block-content-iassist-party-interstitial-overlay block-content-basic-block">
  
    
      


                    <div class="body "><p class="interstitial-opener">Please ask your specialty pharmacy about the JYNARQUE Copay Support Program.</p>
</div>
            
  </div>

  </div>

      </div>
                  <div class="interstitial thirdparty-interstitial">
            <div class="region region-interstitial3p">
    <div id="block-3rdpartyinterstitial" class="custom-block---rdpartyinterstitial block-content-3rd-party-interstitial block-content-basic-block">
  
    
      


                    <div class="body "><p class="interstitial-opener">You are now leaving</p>

<p class="interstitial-domain">JYNARQUEHCP.COM</p>

<p class="interstitial-copy">Please be aware that Otsuka is not responsible for the content on the external website you are about to enter.</p>
</div>
            
  </div>

  </div>

          <a href="#" id="accept3p" class="button external-link-popup-disabled">OK</a>
          <a href="#" id="cancel3p" class="button-transparent cancel-button">CANCEL</a>
      </div>
          </div>
    </div>
  <button id="interstitial-close">Cancel</button>
  </div>
</div>

  </div>

    







<section id="drawer-isi" class="isi-tray jsIsiContainer isi-drawer-expanded resizing">

	<!--<div id="isi-drawer-wrapper" class="isi-drawer-collapsed">-->

    <div class="isi-header">
        <div class="isi-header-wrap">
            <div class="drawer-title"><h2>INDICATION and IMPORTANT SAFETY INFORMATION</h2>
</div>
            <button class="isi-btn jsIsiMinimize" data-oapigtmcategory="Button Clicks" data-oapigtmaction="ISI" data-oapigtmlabel="SEE MORE">
              <span class="jsSwapText jsSwapTextExpand hide">SEE MORE</span>
              <span class="jsSwapText jsSwapTextCollapse">MINIMIZE</span>
              <span class="isi-btn-icon"></span>
            </button>
        </div>
    </div>
	
	<div class="isi isi-block isi-drawer-content isi-content-wrap">
		<div class="jcf-scrollable jcf-container mCustomScrollbar">
      <div class="isi-drawer-content-heading"><h2>INDICATION and IMPORTANT SAFETY INFORMATION</h2>
</div>
      <p class="subtitle subtitle-blue"><span class="nobr">JYNARQUE</span> is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).</p><div class="fake-box"><p class="box-title mobile-only subtitle-blue"><strong>WARNING: RISK OF SERIOUS LIVER INJURY</strong></p><p class="center box-title desktop-only tablet-only subtitle-blue"><strong>WARNING: RISK OF SERIOUS LIVER INJURY</strong></p><ul><li class="jsIsiVisible-mob"><span class="nobr"><strong>JYNARQUE<sup>®</sup> (tolvaptan)</strong></span><strong> can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported</strong></li><li class="jsIsiVisible-dt"><strong>Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of&nbsp;hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity</strong></li><li><strong>Because of the risks of serious liver injury, </strong><span class="nobr"><strong>JYNARQUE</strong></span><strong> is available only through a Risk Evaluation and Mitigation Strategy program called the Tolvaptan for ADPKD Shared System REMS</strong></li></ul></div><p class="subtitle"><strong>CONTRAINDICATIONS:</strong></p><ul><li>History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease</li><li>Taking strong CYP3A inhibitors</li><li>With uncorrected abnormal blood sodium concentrations</li><li>Unable to sense or respond to thirst</li><li>Hypovolemia</li><li>Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product</li><li>Uncorrected urinary outflow obstruction</li><li>Anuria</li></ul><p><strong>Serious Liver Injury:</strong> JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD&nbsp;experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.</p><p><strong>Hypernatremia, Dehydration and Hypovolemia:</strong> JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.</p><p><strong>Inhibitors of CYP3A:</strong> Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.</p><p><strong>Adverse Reactions:</strong> Most common observed adverse reactions with JYNARQUE (incidence &gt;10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.</p><p><strong>Other Drug Interactions:</strong></p><ul><li><strong>Strong CYP3A Inducers:</strong> Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers</li><li><strong>V<sub>2</sub>-Receptor Agonist:</strong> Tolvaptan interferes with the&nbsp;V<sub>2</sub>-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a&nbsp;V<sub>2</sub>-agonist</li></ul><p><strong>Pregnancy and Lactation:</strong> Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.</p><p class="reporting">To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at <span class="nobr">1-800-438-9927</span> or FDA at <span class="nobr">1-800-FDA-1088</span> (<a class="cyan ext-link" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program" data-analytics-name="www.fda.gov/medwatch">www.fda.gov/medwatch</a>).</p><p>Please see <a class="cyan external-link-popup-disabled" href="https://www.otsuka-us.com/media/static/JYNARQUE-PI.pdf" target="_blank" data-analytics-name="FULL PRESCRIBING INFORMATION">FULL PRESCRIBING INFORMATION</a>, including <strong>BOXED WARNING</strong>.</p>

    </div>
	</div>

	<!--</div>--><!--/#isi-drawer-wrapper-->

</section>
<style>
	
	.isi-tray {
		left: 0%;
		width: 100%;
	}
	.isi-drawer-expanded {
		height: 220px;
	}
	.isi-drawer-collapsed {
		height: 200px;
	}

    .isi-tray.isi-drawer-expanded .isi-content-wrap,
    .isi-tray.isi-drawer-expanded .isi-content-wrap>div {
        height: calc(50vh - 380px);
    }
    @media all and (min-width: 768px) {
        .isi-tray.isi-drawer-expanded .isi-content-wrap,
        .isi-tray.isi-drawer-expanded .isi-content-wrap>div {
            height: calc(50vh - 220px);
        }
    }
}

</style>


    
    
<footer>
    <div class="footer-container">

                <div class="footer-row">
            <div class="footer-nav">
                  <div class="region region-footer-nav">
    <nav role="navigation" aria-labelledby="block-jynarque-hcp-footer-menu" id="block-jynarque-hcp-footer" class="custom-block--jynarque-hcp-footer" data-test='privacy-menu'>
            
  <div class="visually-hidden" id="block-jynarque-hcp-footer-menu">Footer menu</div>
  

        
              <ul block="block-jynarque-hcp-footer" region="footer_nav" data-test="footer-menu">
              <li>

                <a href="https://www.otsuka-us.com/privacy-policy" target="_blank" class="ext-link">Privacy Policy</a>
              </li>
          <li>

                <a href="https://www.otsuka-us.com/terms-and-conditions" target="_blank" class="ext-link">Terms of Use</a>
              </li>
        </ul>
  


  </nav>

  </div>

            </div>
        </div>
        
        <div id="mobile-tablet-branding" class="footer-row">
            <div class="footer-otsuka">
                  <div class="region region-footer-branding-otsuka">
    <div id="block-otsukabrandingfooter" class="custom-block--otsukabrandingfooter block-content-otsuka-branding-footer block-content-basic-block">
  
    
      


                    <div class="body "><p><a class="ext-link" href="https://www.otsuka-us.com/" data-analytics-name="Otsuka America Pharmaceutical, Inc., Logo" target="_blank" aria-label=" (opens in a new window)"><img src="../sites/g/files/qhldwo11641/files/inline-images/otsuka_logo2.png" data-entity-uuid="c466d6d1-5a41-4fbc-b91a-a1c601e50800" data-entity-type="file" alt="Otsuka America Pharmaceutical, Inc., Logo" width="492" height="98" loading="lazy"></a></p></div>
            
  </div>

  </div>

            </div>
        </div>

        <div id="desktop-bottom-footer-row">
            <div class="desktop-credits-wrapper">
                <div class="footer-row">
                        <div class="footer-otsuka desktop" data-test='navbar-branding'>
                              <div class="region region-footer-branding-otsuka">
    <div id="block-otsukabrandingfooter" class="custom-block--otsukabrandingfooter block-content-otsuka-branding-footer block-content-basic-block">
  
    
      


                    <div class="body "><p><a class="ext-link" href="https://www.otsuka-us.com/" data-analytics-name="Otsuka America Pharmaceutical, Inc., Logo" target="_blank" aria-label=" (opens in a new window)"><img src="../sites/g/files/qhldwo11641/files/inline-images/otsuka_logo2.png" data-entity-uuid="c466d6d1-5a41-4fbc-b91a-a1c601e50800" data-entity-type="file" alt="Otsuka America Pharmaceutical, Inc., Logo" width="492" height="98" loading="lazy"></a></p></div>
            
  </div>

  </div>

                        </div>
                        <div class="footer-credits">
                            
                        </div>
                </div>

                <div class="footer-row">
                    <div class="footer-mobile-left">
                        <div class="footer-copyright" data-test='copyright'>
                              <div class="region region-footer-copyright">
    <div id="block-otsukacopyright" class="custom-block--otsukacopyright">
  
    
      ©2025 Otsuka America Pharmaceutical, Inc.
  </div>
<div id="block-sitecopyright" class="custom-block--sitecopyright block-content-site-copyright block-content-basic-block">
  
    
      


                    <div class="body "><p>All rights reserved.</p></div>
            
  </div>

  </div>

                        </div>
                        <div class="footer-review-date">
                              <div class="region region-footer-review-date">
    <div id="block-prcdate" class="custom-block--prcdate">
  
    
      <span class="prc-info-date" data-test='prc-date'>April 2025</span>
  </div>


  </div>

                        </div>
                        <div class="footer-prc-code">
                              <div class="region region-footer-prc-code">
    <div id="block-prccode" class="custom-block--prccode">
  
    
      <span class="prc-info-code" data-test='prc-code'>10US25EBP0095</span>
  </div>


  </div>

                        </div>
                    </div>
                </div>
            </div>
            
        </div>    
    </div>
</footer>    <script src="../sites/g/files/qhldwo11641/files/js/optimized/js_5lyEgtuYzFbknt789sXbvgY6WOEBhn68zCRaGR5wIJc.pydd31qeaVwnZ7zmVFZER7RdslYTSa4L05Z96Bj0rpAfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_G8podNJjOsxKvo_RVe4-f79_ME43boCp5OhhwF87kOc.CmHewv09bU-2iMTQUA9fYmgUfGdx8v6eCV0c0HTKVv0fe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_RpLV1j1SEgkAOBNxIxvzKXRlefOlhPa03lpGt46bJEg.ipSHo_VRPfgKJstENA8BEd0ZaAk6UUuLrs-5LtKGyFwfe04.js?v=10.5.0"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_mFzUkjUxStqgHC8aG7xRbdL6fE1PCi6EiNgqsEIWhqc.akPIL5F6ygowEntokyWY4_Tg4pNQtEi97UIJcojA29M1cee.js?t5xpr9"></script>
<script src="../sites/g/files/qhldwo11641/themes/site/themes/custom/jynarque_hcp/legacy/assets/build/js/components/paragraph/modal-link1cee.js?t5xpr9" defer></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_rpx3pOPcK6hnLQR-Fef4P6UMSJh-ihuV9hqkMm_cMdk.vTghGNUkYqEi22uPg-gGp3H22SpaHZoLjn_xZk1ITwka0fc.js?v=1.x"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_8rI11XUPmo8bNSGc51T6ByOCso4FQ5AktRkneJJL7Nc.AyNUrL50y9uFK4-l6wxy1y5SzvrnEuWYvX8Ai1_oSMca0fc.js?v=1.x"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_aGpgzbkylt8snB-EXgmHtxvxOZAT-qDmrVPgkGVG71I.ojHXLPZwCg6JiUQKM9w4QZF_TUslDSaGc0h3XjA--Zwa0fc.js?v=1.x"></script>
<script src="../sites/g/files/qhldwo11641/files/js/optimized/js_t6WcaYLAw6hjWSihMsQXThEsPYFBj0NBE18VKsjijws.EX9XtAmarEWHxG8VqWLQlmsKC8tS6zrY_UhL31ekHLca0fc.js?v=1.x"></script>
<script src="../modules/custom/react_player/js/dist/app.minfe04.js?v=10.5.0"></script>

    </div>
  </body>


</html>
